Public M&A Day in Frankfurt
Latham hosted our second Public M&A Day in Frankfurt, bringing together senior executives and Latham partners to discuss opportunities in the current public M&A sector. Renowned experts and prominent keynote speakers...more
Robust supply chains are vital to our closely connected global economy. Yet escalating geopolitical tensions, persistent inflation and a fragile macroeconomic outlook are presenting businesses with a fresh wave of supply...more
Ankura is pleased to present an overview of healthcare transactions announced or closed during Q3 2023 in the United States. Total transactions decreased by 13.7% in the third quarter of 2023 after increasing by 4.9% in the...more
Whole-business securitization (WBS), a structured finance product where a company issues secured debt against substantially all of its cash-yielding assets, is now on the radar of dealmakers seeking ways to manage M&A...more
M&A is proving popular with companies looking to reinvigorate their portfolios and adapt to shifting consumer demands - The North American food sector is experiencing a period of transition. Large food producers benefited...more
The healthcare M&A market appears to be steadying. Although deal activity through the year appears slightly below the high-water marks for the corresponding period of 2022, deal activity is generally up from the first quarter...more
Following a period of rapid growth, the fund finance market has reached an inflection point. Once considered a small, esoteric area of the lending landscape, fund finance—loan facilities secured against investor commitments...more
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
M&A started strong in 2022 with robust deal activity and megadeals dominating the landscape that was largely the result of unprecedented spillover from 2021. But then, things took a turn and deals stalled in the second half...more
In 2022, many predicted we would see a spike in M&A due to the economic downturn and the steep drop in startup valuations. However, last year was not the M&A blockbuster that was predicted, and we even saw a drop-off in...more
Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity - Healthcare and pharmaceutical deals continued at a robust pace through 2021, registering the...more
Canadian dealmakers are betting on large overseas purchases as market confidence returns - Canadian dealmakers have become a major presence beyond their borders, conducting a total of 361 outbound deals worth a total of...more
High-growth industries continue to attract investor interest despite COVID disruptions - Vietnam’s M&A activity is set for another robust year following 2020’s potent performance. In the first three quarters, deals with...more
An increase in megadeals reveals growing dealmaker appetite within Italy’s M&A market - Dealmaking confidence appears to be returning within the Italian M&A market. A total of US$57.4 billion-worth of deals announced in...more
The value of healthcare M&A in H1 surpassed pre-pandemic levels - Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more
In what many consider a banner year for fintech megadeals, insurtech has begun to take center stage. In early August 2019, Roper Technologies agreed to acquire life insurance software solutions provider iPipeline for $1.6...more